Glenmark Pharmaceuticals Inc, the US-based unit of Glenmark Pharmaceuticals (NSE:GLENMARK, BOM:532296), has launched its Acetylcysteine Injection, according to a Monday filing to the Indian stock exchanges.
Glenmark acquired the ANDA (abbreviated new drug application) for Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) single-dose vials from Aspen Pharma USA.
The injection is expected to have the same therapeutic effect as Cumberland Pharmaceuticals' listed drug product Acetadote Injection.
As per the IQVIATM sales data, the Acetadote Injection achieved annual sales of around $15.2 million for the 12 months that ended in January.
Shares of the company were up nearly 3% in recent trade.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。